7thSpace Interactive (press release) During the treatment, the cough sensitivity to saline gradually decreased among the budesonide responders but not in the non-responders. Nitric oxide levels decreased very rapidly among the responders. Conclusions: Saline test cannot predict the ...
NASDAQ L) to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES ( budesonide inhalation suspension) 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the Court. Actavis launched its ... and more »
pharmabiz.com At the trial, AstraZeneca contended that the defendants' generic budesonide inhalation suspension products and their use will infringe the claims of the two AstraZeneca patents, should those defendants market their generic products in the US. and more »
7thSpace Interactive (press release) During the treatment, the cough sensitivity to saline gradually decreased among the budesonide responders but not in the non-responders. Nitric oxide levels decreased very rapidly among the responders. Conclusions: Saline test cannot predict the ...
7thSpace Interactive (press release) During the treatment, the cough sensitivity to saline gradually decreased among the budesonide responders but not in the non-responders. Nitric oxide levels decreased very rapidly among the responders. Conclusions: Saline test cannot predict the ...
4-traders (press release) At the trial, AstraZeneca contended that the defendants' generic budesonide inhalation suspension products and their use will infringe the cl...
Benzinga Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and saf...
7thSpace Interactive (press release) During the treatment, the cough sensitivity to saline gradually decreased among the budesonide responders but not in the non-responders. Nitric oxide levels decreased very rapidly among the responders. Conclusions: Saline test cannot predict the ...
Triangle Business Journal Salix reported that in each of the two Phase 3 studies, “a statistically significant proportion of subjects treated with budesonide foam (the Salix treatment) achieved clinical remission compared to subjects treated with placebo foam.” Salix will look ... and more »
WRAL Tech Wire Raleigh-based Salix said today its budesonide foam performed better than a placebo in two phase III clinical trials. The drug, a topical foam, is intend...
